17 results on '"E. Ravano"'
Search Results
2. T-cell receptor gene rearrangement in Epstein-Barr virus infectious mononucleosis
- Author
-
M. Riva, A. Colosimo, A. M. Nosari, E. Ravano, L. Marbello, E. Morra, L. Paris, and S. Veronese
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lymphocytosis ,Mononucleosis ,Biology ,medicine.disease_cause ,Virus ,Young Adult ,Immunophenotyping ,Cervical lymphadenopathy ,medicine ,Humans ,Infectious Mononucleosis ,Gene Rearrangement ,Genes, T-Cell Receptor gamma ,Hematology ,General Medicine ,Gene rearrangement ,medicine.disease ,Epstein–Barr virus ,Oncology ,Infectious disease (medical specialty) ,Immunology ,medicine.symptom - Abstract
This report describes the case of a previously healthy young man who presented with fever, pharyngitis, cervical lymphadenopathy, lymphocytosis, and severe thrombocytopenia. Serological tests for Epstein-Barr virus were diagnostic of a primary Epstein-Barr virus infectious mononucleosis but severe thrombocytopenia aroused the suspicion of a lymphoproliferative disease. T-cell receptor gene analysis performed on peripheral and bone marrow blood revealed a T-cell receptor γ-chain rearrangement without the evidence of malignancy using standard histologic and immunophenotype studies. Signs and symptoms of the infectious disease, blood count, and T-cell receptor gene rearrangement resolved with observation without the evidence of emergence of a lymphoproliferative disease. In the contest of a suspected lymphoproliferative disease, molecular results should be integrated with all available data for an appropriate diagnosis.
- Published
- 2011
3. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
- Author
-
Zappaterra A, Civettini I, Cafro AM, Pezzetti L, Pierini S, Anghilieri M, Bellio L, Bertazzoni P, Grillo G, Minga P, Pioltelli ML, Ravano E, Sassone M, Viganò CV, Volpato EB, Gambacorti-Passerini C, Rossini S, Cairoli R, and Crocchiolo R
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Membrane Glycoproteins, Multiple Myeloma therapy, Multiple Myeloma drug therapy, Antigens, CD34, ADP-ribosyl Cyclase 1, Hematopoietic Stem Cell Mobilization methods, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal pharmacology
- Abstract
Background: Induction with daratumumab-based regimens followed by autologous stem cell transplantation is the current standard for newly diagnosed multiple myeloma (NDMM) patients eligible for intensive chemotherapy. However, concerns emerged regarding potential negative effects following daratumumab-based treatment on CD34+ mobilization. We here compared CD34+ mobilization and clonogenic potential between daratumumab and non-daratumumab based therapy without upfront plerixafor administration among patients affected by NDMM., Materials and Methods: Clinical, mobilization and clonogenic data from 41 consecutively enrolled NDMM patients were analyzed. Patients underwent collection of autologous CD34+ by apheresis at the ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, from January 2021 to March 2023. Clonogenicity analysis was performed on BFU-E and CFU-GM., Results: Seventy-five percent of daratumumab-treated patients underwent >1 apheresis, compared to 24% of non-daratumumab patients (p=0.0017). Daratumumab-treated patients had significantly lower CD34+ count (mean 38 vs 79/μL, respectively; p=0.0011), with a median CD34+ harvest of 3.98×10
6 /kg (range 1.68-9.18) vs 6.87×106 /kg (range 1.63-16.85) in non-daratumumab-treated (p=0.0006). In multivariate analysis the likelihood of undergoing >1 apheresis was significantly higher in older patients (OR 1.2, 95% CI 1-1.4, Z=2.10, p=0.03) and daratumumab-treated patients (OR 15, 95% CI 2.8-129, p=0.004). Moreover, daratumumab-based induction therapy demonstrated an independent negative association with BFU-E colony formation (p=0.0148), even when accounting for patient age and CD34+ levels., Discussion: Our findings underscore the impact of daratumumab-based treatment on CD34+ mobilization in a real-life, upfront plerixafor-free population of NDMM patients. Higher probability of requiring multiple apheresis occurred among daratumumab-treated patients. Interestingly, the observation that daratumumab might negatively impact BFU-E colony formation, independent of CD34+ cell count, offers novel biological perspectives. Appropriate strategies should be adopted by the Apheresis teams to mitigate these potential negative effects.- Published
- 2024
- Full Text
- View/download PDF
4. MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.
- Author
-
Pagani C, Rusconi C, Dalla Pria A, Ravano E, Schommers P, Bastos-Oreiro M, Verga L, Gini G, Spina M, Arcaini L, Steffanoni S, Dalu D, Crucitti L, Lorenzi L, Balzarini P, Cattaneo C, Bongiovanni L, Rosenwald A, Facchetti F, Bower M, Ferreri AJM, Rossi G, Tucci A, and Re A
- Subjects
- Humans, Cyclophosphamide therapeutic use, In Situ Hybridization, Fluorescence, Proto-Oncogene Proteins c-myc genetics, Retrospective Studies, Rituximab therapeutic use, Vincristine therapeutic use, HIV Infections drug therapy, HIV Infections epidemiology, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Abstract: Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the HIV population. Scanty data are available on the prevalence and prognostic impact of MYC rearrangements in HIV-associated LBCL. We conducted a retrospective study to evaluate the clinical effect of MYC rearrangement in HIV-associated LBCL. We evaluated clinical characteristics, treatment received, and outcome of LBCL in patients with HIV with MYC rearrangement (MYC+) and without MYC rearrangement (MYC-). A total of 155 patients with HIV who had received fluorescence in situ hybridization analysis for MYC were enrolled in 11 European centers: 43 with MYC+ and 112 MYC-. Among patients with MYC, 10 had double-/triple-hit lymphomas, and 33 had isolated MYC rearrangement (single-hit lymphoma). Patients with MYC+ had more frequently advanced stage, >2 extranodal site at presentation, and higher proliferative index. There were no significant differences in overall survival and progression-free survival (PFS) between the 2 groups. However, patients with MYC+ received more frequently intensive chemotherapy (iCT) (44%) than (R)CHOP alone (35%) or infusional treatment (DA-EPOCH-R and R-CDE) (19%). Among patients with MYC+, those who received iCT achieved a better outcome than patients who received nonintensive treatment (complete remission, 84% vs 52%; P = .028; 5-year PFS, 66% vs 36%; P = .021). Our retrospective results suggest that HIV-associated LBCL with MYC+ could be considered for an intensive therapeutic approach whenever possible, whereas (R)CHOP seems to give inferior results in this subset of patients in terms of complete remission and PFS., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection.
- Author
-
Peracchi F, Merli M, Rogati C, Ravano E, Puoti M, Cairoli R, and Travi G
- Subjects
- Humans, SARS-CoV-2, Antiviral Agents therapeutic use, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
6. Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review.
- Author
-
Zilioli VR, Muzi C, Pagani C, Ravano E, Meli E, Daffini R, Ravelli E, Cairoli R, and Re A
- Abstract
Along with the fact that classical Hodgkin lymphoma (cHL) in older adults is frequently considered biologically different from cHL in younger patients, its most distinctive feature is its dismal clinical outcome due to the decreased effectiveness and greater toxicity of therapies. Although strategies to mitigate specific toxicities (e.g., cardiological and pulmonary) have obtained some results, in general, reduced-intensity schemes, proposed as an alternative to ABVD, have proved to be less effective. The addition of brentuximab vedotin (BV) to AVD, especially in a sequential scheme, has demonstrated good efficacy. However, the problem of toxicity persists even with this new therapeutic combination, with comorbidities remaining an important prognostic factor. The adequate stratification of functional status is necessary to distinguish between those patients who will benefit from full treatment and those who will benefit from alternative strategies. A simplified geriatric assessment based on the determination of ADL (activity of daily living), IADL (instrumental ADL), and CIRS-G (Cumulative Illness Rating Scale-Geriatric) scores is an easy-to-use tool that permits adequate patient stratification. Other factors of considerable impact on functional status such as sarcopenia and immunosenescence are currently being studied. A fitness-based treatment choice would also be very useful for relapsed or refractory patients, a more frequent and challenging situation than that is found in young cHL patients.
- Published
- 2023
- Full Text
- View/download PDF
7. Intrahospital COVID-19 infection outbreak management: Keep calm and carry on.
- Author
-
Frustaci AM, Pioltelli ML, Ravano E, Di Ruscio F, Campisi DA, Puoti M, and Cairoli R
- Subjects
- Adult, Aged, Cross Infection diagnosis, Cross Infection mortality, Cross Infection therapy, Female, Humans, Male, Middle Aged, COVID-19 mortality, COVID-19 Testing, Disease Outbreaks, SARS-CoV-2, COVID-19 Drug Treatment
- Published
- 2021
- Full Text
- View/download PDF
8. Prognostic Impact of Immunohistochemical p53 Expression in Bone Marrow Biopsy in Higher Risk MDS: a Pilot Study.
- Author
-
Molteni A, Ravano E, Riva M, Nichelatti M, Bandiera L, Crucitti L, Truini M, and Cairoli R
- Abstract
Background and Objectives: Mutations of the TP53 gene have an unfavorable prognosis in Myelodysplastic Syndromes (MDS). The product of the TP53 gene is the p53 protein. Most of the TP53 mutations entail the accumulation of the protein in the nucleus of tumor cells. The immunohistochemical (IHC) staining for p53 can be a surrogate suggesting a mutational status and, if overexpressed, seems to be of prognostic value by itself. The best prognostic cut-off value of overexpression is controversial. The aim of this pilot study is to investigate the correct value from a homogenous group of patients with higher IPSS-R risk MDS., Methods: In sixty consecutive patients diagnosed with MDS and categorized as "intermediate," "high" and "very high" IPSS-risk, the bone marrow biopsies performed at diagnosis were retrospectively re-examined for IHC p53 expression. The result of p53 expression was subsequently related to survival., Results: A worse overall survival was observed both in patients whose IHC p53 expression was ≥5% and ≥ 10% compared to patients with a p53 expression below 5% (p= 0.0063) or 10% (p=0.0038) respectively., Conclusions: The ICH p53 expression in bone marrow biopsy in higher risk MDS was confirmed to have prognostic value. These results indicate more than 10% expression as the best cut off value., Competing Interests: Competing interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
9. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
- Author
-
Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, and Rossi G
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Humans, Italy, Male, Middle Aged, Mutation, Nucleophosmin, Survival Rate, Cytarabine administration & dosage, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute mortality, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Remission Induction
- Abstract
Favorable acute myeloid leukemia (AML) patients (pts.) demonstrate a relatively good outcome with standard induction; thus, pts. are generally not addressed to allogeneic transplant in first remission. However, it is not clear if also in a real-life setting, the outcome is homogeneous in the different favorable molecular groups and which are the parameters significantly associated to an increased relapse risk, useful to suggest the need of an intensified approach. In order to clarify this point, we collected clinical data on consecutive unselected AML pts. assigned to favorable category (modified ELN 2010 due to the inclusion of double-mutated CEBPA-positive cases), diagnosed and treated in six centers of the Italian network Rete Ematologica Lombarda (REL) from 2007 to 2015. We assessed response (CR, mCR), relapse rate (CIR), and outcome (OS, DFS) after first-line treatment. A total of 201 pts. was studied and the analysis was performed globally and in each molecular group: t(8;21)(q22;q22)/RUNX1-RUNX1T1 (30 pts., 14.9%), inv. (16)(p13q22) or t(16;16)(p13q22)/CBFB-MIH11 (35 pts., 17.4%), normal karyotype and mutated NPM1 and negative FLT3-ITD (116 pts., 57.7%) or double-mutated CEBPA (CEBPAdm) (20 pts., 10%). Complete remission (CR) was obtained in 188 pts. (93.5%), molecular CR (mCR) in 114 (67.5%); After a median follow-up of 2.4 years, cumulative incidence of relapse (CIR) was documented in 78 of 188 responding pts. (41%) after a median time of 11.3 months. CIR was higher in the CBFB-MIH11 group, in pts. achieving only a hematological response without mCR (72.1 vs 28.1%, p < 0.001), in older pts. and it resulted independently associated with a lower median cytarabine cumulative dose (CCD). Median OS was not reached: after 5 years it was 66.3%, and median DFS was 5.3 years, both without difference among groups. Molecular CR reached at any time, during or after the end of first-line treatment, was significantly associated with better DFS, and in particular, mCR assessed at the end of treatment was confirmed in multivariate analysis as an independent prognostic factor both for DFS and OS. In conclusion, the present study confirms in a real-life context the overall good prognosis of favorable-risk AML; the achievement of any molecular negativity during first-line treatment, particularly when assessed at the end of treatment, is associated with lower relapse and better survival. Increasing age at diagnosis has a negative prognostic impact, while CCD higher than 18 g/sqm is associated with better outcome.
- Published
- 2018
- Full Text
- View/download PDF
10. A double-hit High-grade B-cell lymphoma with three-way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH.
- Author
-
De Paoli E, Bandiera L, Ravano E, Cesana C, Grillo G, Mancini V, De Canal G, Bonoldi E, and Soriani S
- Abstract
We describe an High-grade B-cell lymphoma case, in which a complex translocation t(3;8;14) with effects on the genes BCL6, MYC, and IGH, was detected. This case could be the first double-hit lymphoma with a single chromosome rearrangement causing the double effect with three genes involved.
- Published
- 2018
- Full Text
- View/download PDF
11. Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy and autologous stem cell transplantation for T-cell lymphoma.
- Author
-
Rossotti R, Rusconi C, Baiguera C, Zilioli VR, Grillo G, Merli M, Ravano E, and Puoti M
- Subjects
- Administration, Oral, Adult, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Hepatitis C complications, Humans, Lymphoma, T-Cell complications, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Lymphoma, T-Cell drug therapy
- Abstract
The role of anti-HCV direct-acting agents (DAAs) is well described in HCV-related lymphoproliferative disorders, whereas few data are available on their use in other malignancies, such as aggressive T-cell lymphomas requiring autologous stem cell transplantation (ASCT). We describe two oncologic cirrhotic patients treated with DAAs who underwent ASCT achieving cure for both diseases. Co-administration of sofosbuvir with cisplatin led an unexpected severe kidney impairment that did not resolve 30 weeks after drug exposure. The optimal timing of DAA administration in the ASCT setting has yet to be defined: our experience shows that co-administration is feasible, but requires close monitoring for adverse events.
- Published
- 2018
12. Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
- Author
-
Molteni A, Riva M, Ravano E, Marbello L, Mancini V, Grillo G, Zucchetti E, Greco R, and Cairoli R
- Subjects
- Adolescent, Adult, Aged, Allografts, Clofarabine, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Recurrence, Retrospective Studies, Salvage Therapy methods, Vidarabine administration & dosage, Adenine Nucleotides administration & dosage, Arabinonucleosides administration & dosage, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute prevention & control, Vidarabine analogs & derivatives
- Abstract
For refractory or relapsed acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation is the only curative treatment option, but the disease must be in remission before this can be attempted. "Salvage" therapy regimens containing high-dose cytarabine plus fludarabine or cladribine with or without anthracyclines or plus mitoxantrone and etoposide fail in 30-50% of cases. We report the outcome of 14 patients treated with a clofarabine-based treatment administered after at least one failed fludarabine-based "salvage" attempt in a "real life" (outside a clinical trial) context. No death related to the clofarabine-based treatment was observed. Four of the 14 patients (29%) reached complete remission and one (7%) achieved a reduction of marrow blasts to fewer than 10%. Three of these five patients were successfully transplanted and have shown a long-term survival. The small number of this group of patients does not permit the identification of clinical features clearly related to a favorable outcome, but we note that all the three long-term survivals were FLT3 wild type. Clofarabine-based "salvage therapy" in patients with very poor expectancy is feasible even after a fludarabine-based salvage attempt, albeit with success only in a small percentage of cases (3/14 = 21%).
- Published
- 2017
- Full Text
- View/download PDF
13. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
- Author
-
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, and Morra E
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Female, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute epidemiology, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Myelodysplastic Syndromes epidemiology, Myelodysplastic Syndromes pathology, ROC Curve, Retrospective Studies, Risk Factors, Young Adult, Antimetabolites, Antineoplastic therapeutic use, Azacitidine therapeutic use, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes drug therapy
- Abstract
5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
- Author
-
Molteni A, Riva M, Cesana C, Speziale V, Nichelatti M, Scarpati B, Greco R, Ravano E, Cairoli R, Rossini S, and Morra E
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Bone Marrow Cells metabolism, Bone Marrow Examination, Cell Count, Female, Humans, Immunophenotyping, Male, Middle Aged, Myelodysplastic Syndromes mortality, Prognosis, Bone Marrow pathology, Bone Marrow Cells pathology, Flow Cytometry, Myelodysplastic Syndromes diagnosis
- Abstract
Objective: The medullar blast count is a milestone in the prognostic assessment in myelodysplastic syndromes (MDS). The optical microscopy (OM) may sometimes be inaccurate in this disease. The aim of this work is to test the flow immunocytometric (FCM) determinations of medullar immature cells (CD45(±) ) and the expression, among them, of CD33, CD34, and CD117 markers, for their prognostic relevance., Methods: In a retrospective analysis of 98 patients affected by MDS, the IPSS was re-calculated by means of the FCM determination of blasts. Survival of patients at low or intermediate-1 IPSS risk was compared with the survival of patients at intermediate-2 or high IPSS risk. In the 64 cases with OM blast count lower than 5%, the survival of patients with the FCM count of medullar blasts ≤2% was compared with that of patients with FCM count >2%., Results: Each single marker had a prognostic weight comparable to the optical blast count. The FCM blast count was particularly efficient in distinguishing the risk of having up to 2% or more than 2% of blasts in patients without OM excess of blasts., Conclusion: This method is interesting as prognostic tool, especially in patients without excess of blast., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
15. Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica Lombarda".
- Author
-
Molteni A, Riva M, Pellizzari A, Borin L, Freyrie A, Greco R, Ubezio M, Bernardi M, Fariciotti A, Nador G, Nichelatti M, Ravano E, and Morra E
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Ferritins blood, Humans, Iron blood, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Retrospective Studies, Transfusion Reaction, Young Adult, Blood Cell Count, Erythrocyte Indices, Iron Chelating Agents therapeutic use, Myelodysplastic Syndromes blood, Myelodysplastic Syndromes therapy
- Abstract
To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the "Rete Ematologica Lombarda". According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
16. Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the "International Working Group" criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience.
- Author
-
Molteni A, Riva M, Greco R, Nichelatti M, Ravano E, Marbello L, Nosari A, and Morra E
- Subjects
- Adult, Aged, Aged, 80 and over, Anemia diagnosis, Databases, Factual, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Prognosis, ROC Curve, Risk Factors, Treatment Outcome, Anemia drug therapy, Anemia etiology, Erythropoietin therapeutic use, Myelodysplastic Syndromes complications
- Abstract
The Hellström-Lindberg score (HLS) (1997) is designed to predict erythroid response to erythropoietin treatment in myelodysplastic patients. In order to test the validity of this scoring system, 58 patients affected by myelodysplastic syndrome, treated with a "standard dose" approach between 2001 and 2010, were analyzed. The response to erythropoietin treatment was evaluated in accordance with the "international working group" (IWG) criteria. Among the patients only two were scored "poor," 12 "intermediate," and 44 "good" (15 of whom were scored "3" and 29 "4"). Although the system was verified as a predictive tool for response to erythropoietin therapy, we noted that of patients scored as "good," those with a numerical score of "4" responded more frequently than did those scored "3", as evaluated under both the 2006- and 2000-IWG ("major response") criteria. The modest response rate in patients scoring "3" did not show a difference in response rate in comparison to the "intermediate" group. The present data suggest that only patients scoring "4" on the scale may show an adequate response to the standard dose erythropoietin therapy, while frontline high-dose therapy should be offered to other patients. A further analysis considering endogenous erythropoietin as a possible determinant of response revealed the optimal cut-off value of 80 mIU/mL, instead of the value of 100 mIU/mL utilized by the HLS.
- Published
- 2013
- Full Text
- View/download PDF
17. T-cell receptor gene rearrangement in Epstein-Barr virus infectious mononucleosis.
- Author
-
Marbello L, Riva M, Veronese S, Nosari AM, Ravano E, Colosimo A, Paris L, and Morra E
- Subjects
- Humans, Infectious Mononucleosis pathology, Male, Young Adult, Gene Rearrangement, Genes, T-Cell Receptor gamma genetics, Infectious Mononucleosis genetics, Infectious Mononucleosis physiopathology
- Abstract
This report describes the case of a previously healthy young man who presented with fever, pharyngitis, cervical lymphadenopathy, lymphocytosis, and severe thrombocytopenia. Serological tests for Epstein-Barr virus were diagnostic of a primary Epstein-Barr virus infectious mononucleosis but severe thrombocytopenia aroused the suspicion of a lymphoproliferative disease. T-cell receptor gene analysis performed on peripheral and bone marrow blood revealed a T-cell receptor γ-chain rearrangement without the evidence of malignancy using standard histologic and immunophenotype studies. Signs and symptoms of the infectious disease, blood count, and T-cell receptor gene rearrangement resolved with observation without the evidence of emergence of a lymphoproliferative disease. In the contest of a suspected lymphoproliferative disease, molecular results should be integrated with all available data for an appropriate diagnosis.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.